These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The management of schizophrenia. Bennett DH Br J Psychiatry; 1975; Spec No 9():48-54. PubMed ID: 241452 [No Abstract] [Full Text] [Related]
3. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Johnson DA Br J Hosp Med; 1977 Jun; 17(6):546-58. PubMed ID: 18242 [No Abstract] [Full Text] [Related]
4. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Singh MM; Kay SR Biol Psychiatry; 1979 Apr; 14(2):277-94. PubMed ID: 38865 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Lieberman JA Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808 [No Abstract] [Full Text] [Related]
6. Antipsychotic drugs: clinical pharmacology and therapeutic use. Davis JM; Casper R Drugs; 1977 Oct; 14(4):260-82. PubMed ID: 21069 [No Abstract] [Full Text] [Related]
7. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Tada M; Shirakawa K; Matsuoka N; Mutoh S Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255 [TBL] [Abstract][Full Text] [Related]
8. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857 [TBL] [Abstract][Full Text] [Related]
9. [Neuroleptics and the extrapyramidal system]. Haase HJ Arzneimittelforschung; 1978; 28(9):1536-7. PubMed ID: 38814 [No Abstract] [Full Text] [Related]
11. Antipsychotic drugs--an update. Charalampous KD; Keepers GA J Okla State Med Assoc; 1978 Jan; 71(1):6-9. PubMed ID: 23420 [No Abstract] [Full Text] [Related]
12. Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic, and neuroendocrine correlates. Gelder M; Kolakowska T Compr Psychiatry; 1979; 20(5):397-408. PubMed ID: 39704 [No Abstract] [Full Text] [Related]
14. The risks of long-term neuroleptic treatment of schizophrenia: especially depression and akinesia. Rifkin A Acta Psychiatr Scand Suppl; 1981; 291():129-36. PubMed ID: 6113730 [TBL] [Abstract][Full Text] [Related]
15. Lessons from each drug trial. Marder SR Am J Psychiatry; 2007 Mar; 164(3):375-6. PubMed ID: 17329457 [No Abstract] [Full Text] [Related]
17. Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios. Sakalis G; Chan TL; Sathananthan G; Schooler N; Goldberg S; Gershon S Commun Psychopharmacol; 1977; 1(2):157-66. PubMed ID: 342185 [No Abstract] [Full Text] [Related]
18. The clinical use of antipsychotic medications. Coyle JT Med Clin North Am; 1982 Sep; 66(5):993-1009. PubMed ID: 6127455 [No Abstract] [Full Text] [Related]
19. A long-term pilot study of pipothiazine palmitate in chronic schizophrenia. Villeneuve A; Pires A; Jus A; Lachance R; Drolet A Curr Ther Res Clin Exp; 1972 Nov; 14(11):696-706. PubMed ID: 4404626 [No Abstract] [Full Text] [Related]
20. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Peuskens J; Link CG Acta Psychiatr Scand; 1997 Oct; 96(4):265-73. PubMed ID: 9350955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]